Compare CCI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCI | ZTS |
|---|---|---|
| Founded | 1994 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1B | 31.9B |
| IPO Year | 1998 | 2012 |
| Metric | CCI | ZTS |
|---|---|---|
| Price | $78.79 | $76.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | $104.69 | ★ $154.18 |
| AVG Volume (30 Days) | 4.2M | ★ 4.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.95% | 1.86% |
| EPS Growth | ★ 111.25 | 10.05 |
| EPS | 0.34 | ★ 1.42 |
| Revenue | $4,264,000,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | N/A | $5.63 |
| Revenue Next Year | $1.72 | $4.77 |
| P/E Ratio | $232.88 | ★ $54.44 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $73.75 | $71.47 |
| 52 Week High | $115.76 | $160.48 |
| Indicator | CCI | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 46.82 |
| Support Level | $77.89 | $73.39 |
| Resistance Level | $92.92 | $77.99 |
| Average True Range (ATR) | 2.28 | 2.23 |
| MACD | 0.48 | 0.63 |
| Stochastic Oscillator | 55.91 | 73.48 |
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 90% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown Castle has plans to divest its fiber business, which is expected to be finalized in the first half of 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.